Brean Capital Reiterates Buy On Repros Therapeutics Following Long-Term Phase 3 Data
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target, as the company reported results from its one-year Phase 3 safety trial ZA303 comparing Androxal with placebo.
Aschoff noted, “No new safety signals were identified with long-term treatment with Androxal, including no evidence of negative effects on bone mineral density. Also, 79.3% of Androxal-treated men had normal morning testosterone after 12 months of treatment. SAEs appeared to be not Androxal-related. Safety data in ZA303 were consistent with previous trials and Repros reported no new safety signals from ZA303. Of all 317 patients, 5 Androxal-treated patients reported a SAE. One patient had deep vein thrombosis, but that event was secondary to knee replacement. The other cases involved hospitalization for kidney stone, gall stone, perforated appendix, and a hand injury. We look forward to Repros’ Analyst Day on October 31 and its Type C guidance meeting with the FDA in the first half of November to understand the FDA’s stance on the NDA for Androxal. Should the FDA provide no new advice in the meeting, Repros will file an NDA for Androxal around YE14 that includes safety data from ZA303.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 10.8% and a 58.1% success rate. Aschoff has a -38.0% average return when recommending RPRX, and is ranked #236 out of 3337 analysts.